These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 9665362)

  • 21. Lamivudine reduces healthcare resource use when added to zidovudine-containing regimens in patients with HIV infection.
    Lacey L; Gill MJ
    Pharmacoeconomics; 1999; 15 Suppl 1():13-22. PubMed ID: 10537439
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Paediatric AIDS--is now not the right time to act?
    Matchaba PT; Chapanduka ZC
    S Afr Med J; 1997 Oct; 87(10):1343-5. PubMed ID: 9472245
    [No Abstract]   [Full Text] [Related]  

  • 23. Effortless unintentional smoking cessation after lamivudine-zidovudine-indinavir post-exposure anti-HIV chemoprophylaxis.
    Simini B; Lucchesi C
    Addiction; 1999 Jan; 94(1):139-40. PubMed ID: 10665106
    [No Abstract]   [Full Text] [Related]  

  • 24. Occupational exposure to HIV and post-exposure prophylaxis in healthcare workers.
    Kennedy I; Williams S
    Occup Med (Lond); 2000 Aug; 50(6):387-91. PubMed ID: 10994239
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The cost effectiveness of antiretroviral therapy for HIV disease.
    Messori A; Trippoli S; Vaiani M
    N Engl J Med; 2001 Jul; 345(1):68; author reply 68-9. PubMed ID: 11439960
    [No Abstract]   [Full Text] [Related]  

  • 26. Glaxo cuts HIV drug cost for developing world.
    Nature; 1998 Mar; 392(6672):118. PubMed ID: 9515951
    [No Abstract]   [Full Text] [Related]  

  • 27. [Cost effectiveness analysis of highly active antiretroviral therapy in HIV asymptomatic patients].
    Pinto JL; López Lavid C; Badia X; Coma A; Benavides A
    Med Clin (Barc); 2000; 114 Suppl 3():62-7. PubMed ID: 10994566
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Economic analysis of initial HIV treatment. Efavirenz- versus indinavir-containing triple therapy.
    Caro JJ; O'Brien JA; Migliaccio-Walle K; Raggio G
    Pharmacoeconomics; 2001 Jan; 19(1):95-104. PubMed ID: 11252549
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of a post-exposure HIV chemoprophylaxis program for blood exposures in health care workers.
    Marin MG; Van Lieu J; Yee A; Bonner E; Glied S
    J Occup Environ Med; 1999 Sep; 41(9):754-60. PubMed ID: 10491791
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The management of the occupational exposures of health workers to HIV].
    Escribano Hernández A
    Aten Primaria; 1997 Jun; 20(1):54-6. PubMed ID: 9303664
    [No Abstract]   [Full Text] [Related]  

  • 31. Postexposure treatment of HIV.
    Li RW; Wong JB
    N Engl J Med; 1997 Aug; 337(7):499-500; author reply 501. PubMed ID: 9254337
    [No Abstract]   [Full Text] [Related]  

  • 32. Advanced HIV infection treated with zidovudine monotherapy: lifetime values of absolute cost-effectiveness as a pharmacoeconomic reference for future studies evaluating antiretroviral combination treatments. The Osservatorio SIFO sui Farmaci.
    Messori A; Becagli P; Berto V; Trippoli S; Font M; Tosolini F; Venturini F; Martini N
    Ann Pharmacother; 1997 Dec; 31(12):1447-54. PubMed ID: 9416379
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Costs and benefits of multidrug, multidose antiretroviral therapy for prevention of mother-to-child transmission of HIV in the Dominican Republic.
    Schmidt NC; Roman-Pouriet J; Fernandez AD; Beck-Sagué CM; Leonardo-Guerrero J; Nicholas SW
    Int J Gynaecol Obstet; 2012 Mar; 116(3):219-22. PubMed ID: 22196992
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The mother-to-child HIV transmission debate.
    Joubert JR; Beale MW
    S Afr Med J; 1999 Feb; 89(2):106. PubMed ID: 10191849
    [No Abstract]   [Full Text] [Related]  

  • 35. The financial and service implications of splitting fixed-dose antiretroviral drugs - a case study.
    Taylor R; Carlin E; Sadique Z; Ahmed I; Adams EJ
    Int J STD AIDS; 2015 Feb; 26(2):75-80. PubMed ID: 24700200
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of DTG + ABC/3TC versus EFV/TDF/FTC for first-line treatment of HIV-1 in the United States.
    Peng S; Tafazzoli A; Dorman E; Rosenblatt L; Villasis-Keever A; Sorensen S
    J Med Econ; 2015; 18(10):763-76. PubMed ID: 25934146
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New recommendations on health care worker exposure to HIV.
    Woodward J
    STEP Perspect; 1996; 8(3):8-10. PubMed ID: 11364268
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incremental cost-effectiveness of two zidovudine regimens to prevent perinatal HIV transmission in the United States.
    Pinkerton SD; Holtgrave DR; Layde PM
    Prev Med; 2000 Jan; 30(1):64-9. PubMed ID: 10642461
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Toxicity of antiretroviral agents.
    Struble KA; Pratt RD; Gitterman SR
    Am J Med; 1997 May; 102(5B):65-7; discussion 68-9. PubMed ID: 9845500
    [No Abstract]   [Full Text] [Related]  

  • 40. The cost-effectiveness of treatment with lamivudine and zidovudine compared with zidovudine alone: a comparison of Markov model and trial data estimates.
    Mauskopf J; Lacey L; Kempel A; Simpson K
    Am J Manag Care; 1998 Jul; 4(7):1004-12. PubMed ID: 10181990
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.